title: Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.
abstract: OBJECTIVE
  To evaluate the clinical efficacy and safety of rosiglitazone as a once daily treatment for Type 2 diabetes mellitus (DM).
  
  
  METHODS
  Three hundred and sixty-nine patients with Type 2 DM (mean age 63 years; mean body mass index (BMI) 29.4 kg/m2) were enrolled in a double-blind, parallel group, placebo-controlled, dose-ranging study. Patients were randomly assigned to receive placebo or rosiglitazone at doses of 4, 8, or 12 mg daily for 8 weeks.
  
  
  RESULTS
  At 8 weeks, fasting plasma glucose (FPG) decreased significantly in the rosiglitazone 4 mg, 8 mg, and 12 mg groups (-0.9, -2.0 and -1.7 mmol/l; P = 0.0003, < 0.0001, and < 0.0001, respectively) compared with placebo (+0.4 mmol/l). The improvements in FPG were dose ordered for 4 and 8 mg/ day. The 12 mg/day dose produced no additional improvement. There were small decreases in haemoglobin and haematocrit in the rosiglitazone treatment groups. The overall incidence of adverse experiences was similar in all treatment groups, including placebo with no evidence of hypoglycaemia or hepatotoxicity.
  
  
  CONCLUSIONS
  Rosiglitazone improves glycaemic control when given once daily to treat Type 2 diabetes mellitus and is well tolerated at doses up to and including 12 mg.
authors.affiliation: Department of Endocrinology, St. James's Hospital, Dublin, Ireland.
authors.forename: J J
authors.initials: JJ
authors.lastname: Nolan
authors.forename: N P
authors.initials: NP
authors.lastname: Jones
authors.forename: R
authors.initials: R
authors.lastname: Patwardhan
authors.forename: L F
authors.initials: LF
authors.lastname: Deacon
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D015992:Body Mass Index; D002096:C-Peptide / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004311:Double-Blind Method; D005060:Europe; D005260:Female; D019270:Fructosamine / Q000097:blood; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D010919:Placebos; D000077154:Rosiglitazone; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*; D045162:Thiazolidinediones; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D007004:Hypoglycemic Agents; D007328:Insulin; D010919:Placebos; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D019270:Fructosamine